Analysts have clear opinions on MRNA.

There are 6 analysts on the Wall offering 12 month price targets for Moderna in the last 3 months. The average price target is $31.20 with a high forecast of $40.00 and a low forecast of $24.00. The average price target represents a 63.82% increase from the last price of $19.05.
Moderna, Inc. (MRNA) is followed by 6 analysts on the street.

Geulah Livshits from Chardan Capital rates it a Buy with a target of $40.00.

Similarly, 22 days ago Edward Tenthoff of Piper Sandler Reiterated a Buy with a target of $32.00.

The consensus on the street is null.

What does Moderna, Inc.(MRNA) do ?
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna, Inc. (MRNA) Insider Trades